These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19095443)

  • 1. Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.
    Sparks SM; Banker P; Bickett DM; Clancy DC; Dickerson SH; Garrido DM; Golden PL; Peat AJ; Sheckler LR; Tavares FX; Thomson SA; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):981-5. PubMed ID: 19095443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.
    Sparks SM; Banker P; Bickett DM; Carter HL; Clancy DC; Dickerson SH; Dwornik KA; Garrido DM; Golden PL; Nolte RT; Peat AJ; Sheckler LR; Tavares FX; Thomson SA; Wang L; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):976-80. PubMed ID: 19095442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA; Banker P; Bickett DM; Boucheron JA; Carter HL; Clancy DC; Cooper JP; Dickerson SH; Garrido DM; Nolte RT; Peat AJ; Sheckler LR; Sparks SM; Tavares FX; Wang L; Wang TY; Weiel JE
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1177-82. PubMed ID: 19138846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.
    Evans KA; Li YH; Coppo FT; Graybill TL; Cichy-Knight M; Patel M; Gale J; Li H; Thrall SH; Tew D; Tavares F; Thomson SA; Weiel JE; Boucheron JA; Clancy DC; Epperly AH; Golden PL
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4068-71. PubMed ID: 18554908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural investigations of anthranilimide derivatives by CoMFA and CoMSIA 3D-QSAR studies reveal novel insight into their structures toward glycogen phosphorylase inhibition.
    Saqib U; Kumar B; Siddiqi MI
    SAR QSAR Environ Res; 2011; 22(5-6):411-49. PubMed ID: 21607894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors.
    Birch AM; Kenny PW; Simpson I; Whittamore PR
    Bioorg Med Chem Lett; 2009 Feb; 19(3):850-3. PubMed ID: 19103484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Rath VL; Genereux PE; Hageman DL; Levy CB; McClure LD; McCoid SC; McPherson RK; Schelhorn TM; Wilder DE; Zavadoski WJ; Gibbs EM; Treadway JL
    Bioorg Med Chem Lett; 2005 Jan; 15(2):459-65. PubMed ID: 15603973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen phosphorylase inhibitory effects of 2-oxo-1,2-dihydropyridin-3-yl amide derivatives.
    Karis ND; Loughlin WA; Jenkins ID; Healy PC
    Bioorg Med Chem; 2009 Jul; 17(13):4724-33. PubMed ID: 19443226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG; Somsák L
    Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ; Greenhaff PL; MacInnes A; Timmons JA
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors.
    Yoshida T; Sakashita H; Akahoshi F; Hayashi Y
    Bioorg Med Chem Lett; 2007 May; 17(9):2618-21. PubMed ID: 17317162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.
    Whittamore PR; Addie MS; Bennett SN; Birch AM; Butters M; Godfrey L; Kenny PW; Morley AD; Murray PM; Oikonomakos NG; Otterbein LR; Pannifer AD; Parker JS; Readman K; Siedlecki PS; Schofield P; Stocker A; Taylor MJ; Townsend LA; Whalley DP; Whitehouse J
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5567-71. PubMed ID: 16945526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723.
    Zhang L; Liu H
    Expert Opin Ther Pat; 2010 Jul; 20(7):969-73. PubMed ID: 20367521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors.
    Andersen B; Westergaard N
    Biochem J; 2002 Oct; 367(Pt 2):443-50. PubMed ID: 12099891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.
    Somsák L; Nagy V; Vidal S; Czifrák K; Berzsényi E; Praly JP
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5680-3. PubMed ID: 18793852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
    Liang GB; Qian X; Feng D; Biftu T; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1903-7. PubMed ID: 17291750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why.
    Manta S; Xipnitou A; Kiritsis C; Kantsadi AL; Hayes JM; Skamnaki VT; Lamprakis C; Kontou M; Zoumpoulakis P; Zographos SE; Leonidas DD; Komiotis D
    Chem Biol Drug Des; 2012 May; 79(5):663-73. PubMed ID: 22296957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New inhibitors of glycogen phosphorylase as potential antidiabetic agents.
    Somsák L; Czifrák K; Tóth M; Bokor E; Chrysina ED; Alexacou KM; Hayes JM; Tiraidis C; Lazoura E; Leonidas DD; Zographos SE; Oikonomakos NG
    Curr Med Chem; 2008; 15(28):2933-83. PubMed ID: 19075645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
    Bénardeau A; Benz J; Binggeli A; Blum D; Boehringer M; Grether U; Hilpert H; Kuhn B; Märki HP; Meyer M; Püntener K; Raab S; Ruf A; Schlatter D; Mohr P
    Bioorg Med Chem Lett; 2009 May; 19(9):2468-73. PubMed ID: 19349176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
    Feng S; Yang M; Zhang Z; Wang Z; Hong D; Richter H; Benson GM; Bleicher K; Grether U; Martin RE; Plancher JM; Kuhn B; Rudolph MG; Chen L
    Bioorg Med Chem Lett; 2009 May; 19(9):2595-8. PubMed ID: 19328688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.